News
India’s generic obesity drugs ignite global cost war, experts warn
Cheaper Indian versions of semaglutide are cutting treatment costs by up to 90%, threatening Big Pharma dominance and sparking a race to the bottom in drug pricing. Regulators brace for a surge in demand as supply chains scramble to catch up.